Reduction of matrix metalloproteinase-9 activity by the selective phosphodiesterase 4 inhibitor, RP 73-401 in sensitized mice

被引:9
作者
Belleguic, C
Corbel, M
Germain, N
Boichot, E
Delaval, P
Lagente, V
机构
[1] Univ Rennes 1, Fac Sci Pharmaceut & Biol, INSERM, U456, F-35043 Rennes, France
[2] CHR Rennes, Hop Pontchaillou, Serv Pneumol, F-35000 Rennes, France
关键词
phosphodiesterase inhibitor; matrix metalloproteinase; tissue remodelling; bronchoalveolar lavage; (mouse);
D O I
10.1016/S0014-2999(00)00638-5
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Matrix metalloproteinases are particularly potent in degrading basement membrane collagen and other extracellular matrix components. We have investigated the effects of a selective phosphodiesterase 4 inhibitor, RP 73-401 [N-(3,5-dichloropyrid-4-yl)-3-cyclopentyloxy-4-methoxybenzamide], on gelatinase (matrix metalloproteinase-2 and matrix metalloproteinase-9) activity in ovalbumin-sensitized and -challenged mice. Twenty-four hours after the last challenge, matrix metalloproteinase activity was evaluated in the bronchoalveolar lavage fluids by a zymography technique, and a significant increase in matrix metalloproteinase-9, but not matrix metalloproteinase-2, activity was noted. When administered orally (0.3-3 mg/kg) 1 h before each ovalbumin challenge, the selective phosphodiesterase 4 inhibitor, RP 73-401, significantly reduced this increased matrix metalloproteinase-9 activity in bronchoalveolar lavage fluids. Our data suggest that RP 73-401 may modulate tissue remodelling associated with lung inflammatory processes including asthma. (C) 2000 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:369 / 373
页数:5
相关论文
共 14 条
  • [1] Barnette M S, 1999, Prog Drug Res, V53, P193
  • [2] Comparative effects of betamethasone, cyclosporin and nedocromil sodium in acute pulmonary inflammation and metalloproteinase activities in bronchoalveolar lavage fluid from mice exposed to lipopolysaccharide
    Corbel, M
    Lagente, V
    Théret, N
    Germain, N
    Clément, B
    Boichot, E
    [J]. PULMONARY PHARMACOLOGY & THERAPEUTICS, 1999, 12 (03) : 165 - 171
  • [3] Corbel M, 2000, EUR RESPIR REV, V10, P260
  • [4] Halliday JL, 1999, AM J RESP CRIT CARE, V159, pA325
  • [5] Kumagai K, 1999, J IMMUNOL, V162, P4212
  • [6] EFFECTS OF ISOZYME-SELECTIVE PHOSPHODIESTERASE INHIBITORS ON EOSINOPHIL INFILTRATION IN THE GUINEA-PIG LUNG
    LAGENTE, V
    MOODLEY, I
    PERRIN, S
    MOTTIN, G
    JUNIEN, JL
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 1994, 255 (1-3) : 253 - 256
  • [7] Contribution of 92 kDa gelatinase type IV collagenase in bronchial inflammation during status asthmaticus
    Lemjabbar, H
    Gosset, P
    Lamblin, C
    Tillie, I
    Hartmann, D
    Wallaert, B
    Tonnel, AB
    Lafuma, C
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1999, 159 (04) : 1298 - 1307
  • [8] Increased release of matrix metalloproteinase-9 in bronchoalveolar lavage fluid and by alveolar macrophages of asthmatics
    Mautino, G
    Oliver, N
    Chanez, P
    Bousquet, J
    Capony, F
    [J]. AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 1997, 17 (05) : 583 - 591
  • [9] Eosinophils as a source of matrix metalloproteinase-9 in asthmatic airway inflammation
    Ohno, I
    Ohtani, H
    Nitta, Y
    Suzuki, J
    Hoshi, H
    Honma, M
    Isoyama, S
    Tanno, Y
    Tamura, G
    Yamauchi, K
    Nagura, H
    Shirato, K
    [J]. AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 1997, 16 (03) : 212 - 219
  • [10] ROCHE WR, 1989, LANCET, V1, P520